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Background: A subgroup of the NLR (nucleotide binding domain, leucine-rich repeat-containing) proteins and a non-NLR
protein AIM2 are key mediators of the inflammasome.
Results: Cells lacking Nrf2 are defective in the activation of the NLRP3 and AIM2 inflammasome but not the NLRC4
inflammasome.
Conclusion: Nrf2 is an essential mediator of NLRP3 and AIM2 inflammasome activation.
Significance: Nrf2 plays a proinflammatory role by enhancing inflammasome activation.
Despite the number of extensive studies on the immune func-
tion and signaling of inflammasomes in various diseases, the
activating mechanism of inflammasome, especially the NLRP3
inflammasome, is not fully understood. Nuclear factor E2-re-
lated Factor-2 (Nrf2), a key transcription factor that regulates
cellular redox homeostasis, has been reported to play both pro-
tective and pathogenic roles depending on the disease condi-
tions through undefined mechanism. This study reveals an
essential role of Nrf2 in inflammasome activation. LPS stimula-
tion increased Nrf2 protein levels in a Myd88-dependent man-
ner. When compared with wild-type controls, Nrf2-deficient
(Nrf2/) macrophages showed decreased maturation and
secretion of caspase-1 and IL-1 and reduced apoptosis-associ-
ated speck-like protein containing CARD (ASC) speck forma-
tion in response to various NLRP3 and AIM2 inflammasome
stimuli. In contrast, NLRC4 inflammasome activation was not
controlled by Nrf2. Biochemical analysis revealed that Nrf2
appeared in the ASC-enriched cytosolic compartment after
NLRP3 inflammasome activation. Furthermore, mitochon-
drial reactive oxygen species-induced NLRP3 activation also
required Nrf2. Nrf2/ mice showed a dramatic decrease in
immune cell recruitment and IL-1 generation in alum-in-
duced peritonitis, which is a typical IL-1 signaling-dependent
inflammation animal model. This work discovered a critical
proinflammatory effect of Nrf2 by mediating inflammasome
activation.
The activation of inflammasome, a multiprotein cytosolic
complex, leads to caspase-1 activation, which causes the matu-
ration and secretion of inflammatory cytokines IL-1 and
IL-18. A subgroup of NLR2 (nucleotide binding domain, leu-
cine-rich repeat containing) proteins or non-NLR protein
AIM2 together with adaptor protein ASC, assemble to form
individual inflammasome complexes (1– 6). Although the acti-
vating ligands and mechanisms for several inflammasomes
(NLRP1, NLRC4, and AIM2 inflammasome) have been defined,
it remains unclear how other inflammasomes, especially
NLRP3 inflammasome, are activated at the molecular level (7).
A diverse series of exogenous and endogenous agonists can
activate the NLRP3 inflammasome; however, direct binding of
these ligands to NLRP3 has not been clearly demonstrated.
Instead, it is generally accepted that NLRP3 senses a multitude
of disturbances in cellular homeostasis. Consistent with this
notion, recent studies reveal several cell stress-related signaling
pathways that cause NLRP3 activation (7). These signals
include endoplasmic reticulum stress (8), calcium signaling (9,
10), and mitochondria-associated signals such as mitochon-
drial ROS (11, 12), phospholipid cardiolipin (13), and mito-
chondrial DNA (14, 15). Because it has been well documented
that the inflammasome, which leads to caspase-1 protease acti-
vation, has broad biologic and clinical impact, further identifi-
cation of new mediators of inflammasome activation will pro-
vide potential therapeutic targets toward numerous disease
conditions.
Oxidative stress is one established mechanism of inflamma-
tion and tissue damage. Nuclear factor E2-related factor-2
(Nrf2) is an essential transcription factor that mediates cellular
antioxidant responses by regulating the expression of genes
encoding a wide range of phase II detoxifying enzymes and
antioxidants (16 –19). Under non-stressed conditions, Nrf2 is
maintained at low protein levels through a ubiquitin-protea-
some mechanism mediated by cullin-3, an E3 ubiquitin ligase,
and an adaptor protein kelch-like ECH-associated protein 1
(Keap1). During cellular stress conditions, Nrf2 is released from
Keap1 sequestration, and the accumulated Nrf2 is translocated
into the nucleus to initiate gene transcription via the antioxi-
dant response element (ARE). The target genes of Nrf2 include
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those encoding glutathione S-transferases (Gst), NAD(P)H
dehydrogenase, quinone 1 (Nqo1), and heme oxygenase 1
(Hmox1) (16 –19).
Recent studies indicate a protective role of Nrf2 in multiple
inflammatory diseases, such as sepsis (20, 21), asthma (22),
infectious diseases (23–25), and cigarette smoke-induced
emphysema (26). Paradoxically, Nrf2 has also been shown to
play a pathogenic role in metabolic disorders including athero-
sclerosis (27–29), obesity (30), and type 2 diabetes (31), all of
which are typically associated with chronic inflammation. The
seemingly conflicting findings suggest an undefined effect Nrf2
may play in various disease conditions. Here we show an essen-
tial role of Nrf2 in mediating inflammasome activation, which
has been recently implicated in the pathogenesis of metabolic
disorders (12, 32–36). Nrf2 deficiency resulted in defective acti-
vation of the NLRP3 and AIM2 inflammasome but not the
NLRC4 inflammasome. An alum-induced peritonitis animal
model confirmed the critical effect of Nrf2 in IL-1 signaling-
associated inflammation. Nrf2 is present in the ASC-enriched
cytosolic compartment after NLRP3 activation, suggesting a
possibility that Nrf2 may directly contribute to the assembly
of ASC speck that is an essential step for inflammasome
activation.
EXPERIMENTAL PROCEDURES
Mice—Nlrp3/, Nlrc4/, Nrf2/, Myd88/ mice have
been described previously (37–39). C57BL/6 mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME). All
mouse studies were used in accordance with the National Insti-
tutes of Health guide for the Care and Use of Laboratory Ani-
mals and Institutional Animal Care and Use Committees
guidelines of the University of North Carolina Chapel Hill.
Reagents and Antibodies—Rotenone, antimycin A, N-acetyl-
L-cysteine (NAC) and ATP were from Sigma. Ultrapure lipopo-
lysaccharide (LPS), flagellin, nigericin, poly(dA:dT), alhydrogel,
and monosodium urate were purchased from InvivoGen.
Imject Alum was from Pierce. Silica (MIN-U-SIL 15) was from
U. S. Silica. Diphenyleneiodonium (DPI) was from Enzo Life
Sciences. TRIzol reagent was from Invitrogen. X-tremeGENE
HP DNA Transfection Reagent was from Roche Applied Sci-
ence. Transfection reagent Profect P1 was from Targeting Sys-
tems. Disuccinimidyl substrate was from Thermo Scientific.
Antibodies for immunoblotting include anti-caspase-1 (sc-
514), anti--actin (sc-1615 HRP) (Santa Cruz Biotechnology),
anti-NLRP3 (Cryo-2), anti-Asc (AL177) (Adipogen), anti-IL-1
(AF-401-NA) (R&D Systems), and anti-Nrf2 (ab62352) and
anti-HMGB1 (ab18256) (Abcam). Antibodies for flow cytom-
etry include CD11b (M1/70; BioLegend), Ly-6C (HK1.4;
Abcam), and Ly-6G (1A8; Pharmingen).
Cell Culture and Stimulation—Bone marrow-derived macro-
phages (BMMs) were generated in the presence of L-929 con-
ditional medium. Cells were cultured in DMEM complemented
with 10% FCS, 1 mM sodium pyruvate, 1 mM nonessential
amino acid, 100 IU/ml penicillin/streptomycin, and 2 mM
L-glutamine. After pretreatment with ultrapure LPS (200
ng/ml) for 3 h, cells were stimulated with alum (100 g/ml),
silica (50 g/ml), monosodium urate (200 g/ml), and alhydro-
gel (400 g/ml) for 8 h and transfected poly(dA:dT) (1 g/ml)
or flagellin (1 g/ml) for 4 h, as indicated in the figure legends.
Poly(dA:dT) was transfected with X-tremeGENE at a mass-to-
volume ratio of 1:2. Flagellin was transfected with Profect P1 at
a mass-to-volume ratio of 1:5. For ATP or nigericin, cells were
primed with LPS for 6 h followed with ATP (2 mM) or nigericin
(5 M) stimulation for 40 min. Supernatant and cell lysate were
collected for ELISA and Western blot analysis.
Real-time PCR Analysis—Total RNA was extracted from in
vitro cultured BMMs using TRIzol (Invitrogen). cDNA synthe-
sis was performed with Moloney murine leukemia virus reverse
transcriptase (Invitrogen) at 38 °C for 60 min. Real-time PCR
was performed using SYBR Green PCR Master Mix in an ABI
PRISM 7900 sequence detection system (Applied Biosystems).
The -fold difference in mRNA expression between treatment
groups was determined by a standard Ct method. -Actin
was analyzed as an internal control. The primer sequences of
individual genes are available upon request.
Immunoblotting—Electrophoresis of proteins was per-
formed by using the NuPAGE system (Invitrogen) according to
the manufacturer’s protocol. Briefly, cultured BMMs were col-
lected and lysed with radioimmune precipitation assay buffer.
Proteins were separated on a NuPAGE gel and transferred onto
nitrocellulose membranes (Bio-Rad). Appropriate primary
antibodies and HRP-conjugated secondary antibodies were
used, and proteins were detected using the enhanced chemilu-
minescent (ECL) reagent (Thermo Scientific). The images were
acquired with ChemiDoc MP System (Bio-Rad).
ELISA—Cytokines generated by in vitro cultured BMMs
were quantified using the ELISA Set for mouse IL-1, IL-6, or
TNF- (BD Biosciences) according to the manufacturer’s
protocol.
ASC Oligomerization Assay—ASC oligomerization assays
were performed as previously described with minor modifica-
tions (40). BMMs were seeded in 6-well plates (3  106 cells per
well). After the treatment with indicated stimuli, the cells were
washed by cold PBS and resuspended in an ice-cold buffer
(Buffer A: 20 mM HEPES-KOH, pH 7.5, 150 mM KCl, 1% Non-
idet P-40, 0.1 mM PMSF, and protease inhibitor) and lysed by
shearing 10 times through a 21-gauge needle. Nuclei and
unlysed cells were removed by centrifugation at 250  g for 5
min. The cell lysates were then centrifuged at 5000  g for 10
min at 4 °C. After washing twice with PBS, the pellets were
cross-linked with fresh disuccinimidyl substrate (2 mM) for 30
min at 37 °C. The cross-linked pellets were separated in 4 –12%
SDS-PAGE. and immunoblotting was performed.
Immunofluorescence—WT or Nrf2/ BMMs were seeded
on glass-bottom 12-well plates (P12G-1.5–14-F, MatTek
Corp.). After the treatment with different stimuli, cells were
fixed and permeabilized with 4% paraformaldehyde containing
0.1% Triton-X 100 for 20 min at room temperature. The cells
were washed 3 times with 1 PBS and incubated with blocking
buffer (5% BSA, 2% goat serum, 1% Fc block) for 30 min at room
temperature. The samples were incubated with anti-ASC anti-
body (1:200 dilution) in the blocking buffer overnight at 4 °C
followed by the incubation with Alexa Fluor 647 goat anti-
rabbit antibody (1:1000 dilution; A-21244, Invitrogen) for 2 h at
room temperature. Images were acquired with a Zeiss LMS 710
confocal microscope.
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LDH Release Assay—WT or Nrf2/ BMMs were seeded on
96-well plates. After the treatment with indicated stimuli,
supernatants were collected, and LDH activity was determined
with the a cytotoxicity detection kit (LDH) (Roche Applied Sci-
ence). Cells left untreated or treated with 1% Triton X-100 were
used as negative and positive controls, respectively.
Alum-induced Peritonitis—Mice were injected intraperito-
neally with 400 g of alum diluted in sterile PBS. Sixteen hours
later peritoneal lavage was performed, and peritoneal exudate
cells were stained with cell surface markers. Neutrophils and
inflammatory monocytes were identified as CD11bLy-6G
and CD11bLy-6C, respectively. Flow cytometry analysis
was performed on a CYAN flow cytometer. Alternatively, mice
were injected with 600 g of alum, and peritoneal lavage was
performed 4 h later. IL-1 was measured by ELISA.
Statistical Analysis—Statistical analysis was carried out with
Prism 5 for Macintosh. Results were presented as the mean 
S.D., and unpaired Student’s t test (one tailed) was applied to
evaluate significance. p values less than 0.05 were considered
statistically significant.
RESULTS
Nrf2 Protein Accumulation after LPS Stimulation—It is well
accepted that Nrf2 protein level is tightly controlled by protea-
somal degradation via cullin-3- and Keap1-mediated ubiquiti-
nation (16 –19). To study the effect of Nrf2 in macrophages, we
initially examined if Nrf2 can be induced by LPS, a widely used
TLR4 ligand that causes classical macrophage activation. In
BMMs, the protein level of Nrf2 increased from 4 h after LPS
stimulation (Fig. 1A), whereas Nrf2 transcript did not increase
(Fig. 1B). These findings suggest that LPS-induced Nrf2 protein
accumulation independent of transcription. Furthermore, LPS-
induced Nrf2 accumulation is largely dependent of MyD88, a
key adaptor protein of TLR signaling, as MyD88 deficiency
(Myd88/) dramatically attenuated LPS-increased Nrf2 pro-
tein level (Fig. 1C). Similarly, LPS-induced increase of NLRP3
and pro-IL-1 were also dramatically blunted in Myd88/
BMMs.
Nrf2/ Macrophages Showed Defective Activation of the
NLRP3 and AIM2 Inflammasome—Previous studies suggest an
inhibitory effect of Nrf2 in NF-B-dependent cytokine produc-
tion in macrophages (20, 21). Yet the significance of Nrf2 in
inflammasome activation has not been fully characterized. To
examine the role of Nrf2 in this capacity, we treated LPS-
primed BMMs with a series of stimuli that activate the NLRP3
inflammasome. As expected, alum (Fig. 2A) and silica (Fig. 2B)
induced IL-1 production from WT BMMs in a dosage (Fig. 2,
A and B, left panels) and time (Fig. 2, A and B, right panels)-de-
pendent manner. However, Nrf2/ BMMs generated signifi-
cantly less IL-1 in response to alum and silica stimulation. IL-6
production was comparable between WT and Nrf2/ BMMs
(Fig. 2C), indicating that the defective IL-1 generation was not
due to a common failure in cytokine production in Nrf2/
BMMs. Nrf2/ BMMs showed a similar defect in IL-1 pro-
duction when treated with another two crystalline reagents,
alhydrogel (Fig. 2D) and monosodium urate (Fig. 2E). Further-
more, Nrf2/ BMMs showed significantly less IL-1 produc-
tion (Fig. 2F) and cell death (Fig. 2G) but similar IL-6 produc-
tion (Fig. 2H) in response to ATP and nigericin, suggesting that
the critical effect of Nrf2 in IL-1 production is not limited to
crystalline reagents. These data indicate that Nrf2 is essential
for NLRP3 inflammasome activation.
We next tested if Nrf2 is important for the activation of other
inflammasomes, namely AIM2 and NLRC4 inflammasome.
Transfected poly(dA:dT) and flagellin are well characterized
ligands that activate AIM2 and NLRC4 inflammasome, respec-
tively. Nrf2/ BMMs generated significantly less IL-1 in
response to transfected poly(dA:dT) with (Fig. 2I) or without
(Fig. 2J) LPS priming, indicating that Nrf2 is important for
AIM2 inflammasome activation. In contrast, the production of
IL-1 (Fig. 2K), IL-6 (Fig. 2L), and cell death (Fig. 2 M) were
comparable between WT and Nrf2/ BMMs in response to
transfected flagellin, suggesting that Nrf2 is dispensable for
NLRC4 inflammasome activation. As controls, we showed that
IL-1 production and cell death were abolished in Nlrc4/
BMMs.
Next we measured the cleavage of pro-IL-1 and pro-
caspase-1 to biochemically evaluate inflammasome activation.
Alum and silica caused procaspase-1 and pro-IL-1 processing
to their mature forms in LPS-primed WT BMMs (Fig. 3A).
However, these effects were abolished in Nrf2/ BMMs (Fig.
3A). Similar data were acquired when the cells were stimulated
with ATP, nigericin (Fig. 3B), or transfected poly(dA:dT) (Fig.
3C). These results indicate that Nrf2 is essential for NLRP3 and
AIM2 inflammasome activation. In contrast, transfected flagel-
lin promoted normal IL-1 and caspase-1 maturation in
Nrf2/ BMMs but not in Nlrc4/ BMMs, indicating that
Nrf2 is not required for NLRC4 inflammasome activation (Fig.
3D).
Nrf2 is a vital transfection factor that regulates the transcrip-
tion of thousands of genes (41, 42). We asked if the defective
inflammasome activation was due to the impaired gene tran-
FIGURE 1. LPS induces Nrf2 protein accumulation. A and B, BMMs gener-
ated from naïve C57BL/6 mice were stimulated with LPS (400 ng/ml) for the
indicated periods. Protein (A) and transcript (B) of Nrf2 was measured by
immunoblotting and RT-PCR, respectively. C, BMMs generated from WT or
Myd88/ mice were stimulated with LPS (400 ng/ml) for the indicated peri-
ods. Immunoblotting was performed to measure the protein levels of indi-
cated molecules. Values in B are expressed as the mean  S.D., and the results
are representative of three independent experiments.
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scription of inflammasome components in Nrf2/ BMMs.
However, Nrf2 is not required for up-regulation of genes
encoding inflammasome-related molecules, including Nlrp3,
Pycard, and Il1b in response to LPS stimulation (Fig. 3E). As
positive controls, the induction of two classical target genes of
Nrf2, Nqo1 and Hmox1, was totally abolished in Nrf2/
BMMs (Fig. 3F). In addition, protein levels of inflammasome-
related molecules were comparable between WT and Nrf2/
BMMs in response to LPS alone (Fig. 3G) or LPS plus inflam-
masome stimuli (Fig. 3, A–D). These data suggest that Nrf2
is not required for expression of the acknowledged inflam-
masome components.
Nrf2 Is Required for ASC Speck Formation upon NLRP3 and
AIM2 Inflammasome Activation—In addition to the matura-
tion and secretion of procaspase-1 and pro-IL-1, another hall-
mark of inflammasome activation is the formation of ASC
speck. This large protein complex assembled by ASC is essen-
tial for caspase-1 activation (43). Next, we tested if Nrf2 con-
trols ASC speck formation upon NLRP3 and AIM2 inflam-
masome activation. Endogenous ASC immunostaining showed
that ATP or nigericin stimulation caused ASC speck formation
in 60% of LPS-primed WT BMMs (Fig. 4A). In contrast, sig-
nificantly less Nrf2/ BMMs contained ASC speck after sim-
ilar treatments (Fig. 4A), suggesting that Nrf2 is important for
FIGURE 2. Nrf2 is required for the NLRP3 and AIM2 inflammasome activation. A–H, LPS-primed WT or Nrf2/ BMMs were stimulated with a series of
agonists at indicated dosages, including alum (A and C), silica (B and C), alhydrogel (D), monosodium urate (MSU) (E), ATP or nigericin (F–H). Cytokines in
supernatants were measured by ELISA (A–G). Cell cytotoxicity was determined by LDH release assay (H). I, LPS-primed WT or Nrf2/ BMMs were stimulated
with transfected poly(dA:dT) for 4 h (I). J, naïve WT or Nrf2/ BMMs were stimulated with transfected poly(dA:dT) for 16 h. K–M, WT, Nrf2/, or Nlrc4/ BMMs
were untreated or primed with 400 ng/ml LPS for 3 h followed by the stimulation with transfected flagellin for 4 h. The treatment of cells with transfection
reagent alone was included as “transfection control.” IL-1 (K) and IL-6 (L) in supernatants were measured by ELISA. Cell cytotoxicity was determined by LDH
release assay (M). Values are expressed as the mean  S.D., and the results are representative of three independent experiments. *, p  0.05, versus controls.
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ASC speck formation. Similarly, Nrf2/ BMMs showed defec-
tive ASC speck formation in response to transfected poly(dA:
dT) (Fig. 4B). These data are consistent with our previous find-
ings and further strengthens the critical role of Nrf2 in NLRP3
and AIM2 inflammasome activation.
Subsequently, we wanted to determine the role of Nrf2 in
NLRP3-dependent ASC speck formation with a well estab-
lished biochemical assay (40). As expected, the stimulation of
LPS-primed WT BMMs with ATP, nigericin (Fig. 4C), alum, or
silica (Fig. 4D) caused the formation of detergent-resistant ASC
aggregates. Due to the usage of cross-linking reagent disuccin-
imidyl substrate, aggregated ASC formed dimers or oligomers.
However, ASC aggregates and oligomerization were largely
diminished in similarly treated Nrf2/ BMMs. Interestingly,
ASC appeared in ASC aggregate after inflammasome activation
(Fig. 4, C and D). These findings revealed a critical role of Nrf2
in ASC speck formation and suggested a possibility that Nrf2
may mediate inflammasome activation by directly promoting
ASC speck formation.
ROS Mediates Inflammasome Activation via Nrf2—As a typ-
ical Nrf2 activator, ROS modifies the critical cysteine thiols of
Keap1 and Nrf2, which leads to their dissociation and Nrf2
accumulation (16 –19). Interestingly, ROS has also been sug-
gested as an important mechanism that either primes or acti-
vates the NLRP3 inflammasome (7, 11, 44), although contro-
versy still exists (45). We thereby hypothesized that Nrf2 is an
effector molecule that is involved in ROS-mediated inflam-
masome activation. Two inhibitors of mitochondrial respira-
tory function, rotenone and antimycin, have previously been
shown to activate the NLRP3 inflammasome by increasing
FIGURE 3. Nrf2 mediates caspase-1 and IL-1 processing. A–C, resting or LPS-primed BMMs generated from WT or Nrf2/ mice were stimulated with a series
of agonists at indicated dosages, including alum or silica (A), ATP or nigericin (B), and transfected poly(dA:dT) (C). Immunoblotting for caspase-1 and IL-1 was
performed in supernatants and cell lysates as indicated in the figure. E–G, WT or Nrf2/ BMMs were stimulated with LPS (400 ng/ml) for the indicated periods.
Transcripts of Nlrp3, Pycard, Casp1, and Il1b (E) and Nqo1 and Hmox1 (F) were determined by RT-PCR. Proteins of NLRP3, procaspase-1, pro-IL-1, and ASC were
measured by ELISA (G). Values in E and F are expressed as the mean  S.D., and the results are representative of two independent experiments. *, p  0.05,
versus controls.
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mitochondrial ROS generation (11). Indeed, we found that
rotenone and antimycin caused IL-1 release (Fig. 5A) and the
cleavage of pro-IL-1 and procaspase-1 (Fig. 5C), responses
dependent on NLRP3 activation. To confirm that these inhibi-
tors work primarily through NLRP3, we showed that IL-6 gen-
eration was not affected by the treatments (Fig. 5B). Impor-
tantly, these effects were largely diminished in similarly treated
Nrf2/ BMMs, indicating that Nrf2 is important for mito-
chondrial ROS-mediated inflammasome activation. Rotenone
and antimycin did not further enhance LPS-induced Nrf2 pro-
tein accumulation, suggesting that Nrf2 protein level was satu-
rated by LPS treatment alone.
ROS inhibition has been shown to block the priming or acti-
vation of the NLRP3 inflammasome (44, 46). We found that
NAC and DPI, two widely used ROS inhibitors, dramatically
decreased LPS-induced Nrf2 protein accumulation with mini-
mal effect on other inflammasome-related protein such as
NLRP3, procaspase-1, and pro-IL-1 (Fig. 5D). This indicates
that Nrf2, but not other inflammasome components, is the
major target of ROS inhibitors, a result consistent with the con-
cept that ROS is a classical activating mechanism for Nrf2 (16 –
19). ROS inhibitor-mediated decreases in Nrf2 is functionally
important, as NAC or DPI decreased IL-1 release induced by
silica (Fig. 5E) or poly(dA:dT) (Fig. 5F) in WT, but not Nrf2/,
BMMs. When ROS inhibitors were added 4 h after LPS prim-
ing, neither LPS-induced Nrf2 accumulation (Fig. 5G) nor
IL-1 release (Fig. 5H) by silica was inhibited, suggesting that
Nrf2 accumulation paralleled with inflammasome activation.
These findings indicate that ROS inhibitors minimized NLRP3
inflammasome activation via Nrf2.
Attenuated Alum-induced Peritonitis in Nrf2/ Mice—We
next evaluated the in vivo effect of Nrf2-mediated inflam-
FIGURE 4. Nrf2 is required for ASC speck formation upon NLRP3 and AIM2 inflammasome activation. A and B, WT or Nrf2/ BMMs were primed with 400
ng/ml LPS for 6 h followed by the stimulation with ATP (2 mM) or nigericin (10 M) for 20 min (A) or transfected poly (dA:dT) (5 g/ml) (B) for 4 h. Immunostaining
of endogenous ASC was performed (left panels). Quantification of ASC speck was performed by counting cells in 10 individual filed (right panels). C and D,
LPS-primed WT or Nrf2/ BMMs were stimulated with ATP or nigericin (C) and alum or silica (D). Detergent-resistant ASC aggregate was isolated, and
immunoblotting of ASC and Nrf2 was performed in cross-linked pellets (upper panels) and in cell lysates (lower panels). Values are expressed as the mean  S.D.,
and the results are representative of two independent experiments. *, p  0.05, versus controls.
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masome activation by utilizing an alum-induced peritonitis
model in our mice. Intraperitoneal administration of alum
induces IL-1 signaling-dependent inflammatory cell recruit-
ment (47). We found that alum induced immune cell recruit-
ment in the peritoneal cavity including Ly-6G neutrophils
and Ly-6C inflammatory monocytes in WT mice (Fig. 6,
A–D). However, Nrf2/ mice showed a significantly less
recruitment of immune cells, supporting a critical proinflam-
matory role of Nrf2 in alum-induced peritonitis. Furthermore,
Nrf2/ mice generated significantly less IL-1 in peritoneal
cavity 4 h after alum intraperitoneal injection (Fig. 6E). Overall,
this study suggests that Nrf2 is important for inflammasome-
mediated cytokine responses both in vitro and in vivo.
DISCUSSION
Inflammasome assembly is triggered by various danger sig-
nals, including those from both endogenous and exogenous
sources. Oxidative stress, a commonly observed feature during
FIGURE 5. Nrf2 is important for ROS-mediated NLRP3 inflammasome activation. A–C, WT, Nrf2/, or Nlrp3/ BMMs were untreated or primed with 400
ng/ml LPS for 3 h followed by the stimulation with rotenone (20 M) or antimycin (40 g/ml) for 6 h. IL-1 (A) and IL-6 (B) in supernatants were measured by
ELISA. Immunoblotting for caspase-1 and IL-1 were performed in supernatants and cell lysates (C). D, WT BMMs were untreated or pretreated with NAC or DPI
for 30 min followed by stimulation with LPS (400 ng/ml) for 6 h. Immunoblotting (left) and densitometric analysis (right) for Nrf2 and NLRP3 inflammasome
component molecules were performed. E and F, WT or Nrf2/ BMMs were untreated or pretreated with NAC or DPI for 30 min followed by stimulation with LPS
(400 ng/ml) for 3 h then silica (100 g/ml) for 6 h (E) or transfected poly(dA:dT) for 4 h (F). IL-1 in supernatants was measured by ELISA. G and H, WT BMMs were
treated with LPS for 4 h followed by the stimulation with silica in the absence or presence of NAC or DPI for 4 h. Immunoblotting was performed (G). IL-1 in
supernatants was measured by ELISA (H). Values are expressed as the mean  S.D., and the results are representative of four independent experiments. * p 
0.05, versus controls.
Nrf2 Mediates Inflammasome Activation
17026 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289 • NUMBER 24 • JUNE 13, 2014
inflammatory responses, has been indicated as an important
upstream signaling mediator contributing toward inflam-
masome activation (7, 11, 48). Nrf2 is a pivotal transcription
factor that maintains intracellular redox homeostasis through
regulating the transcription of antioxidant genes (16 –19). As a
result, Nrf2 deficiency has been shown to cause an elevated
ROS level, which is detrimental to normal cell functions and
promotes cell death (16 –19). Based on the well defined anti-
oxidative effect of Nrf2, we initially hypothesized that Nrf2 defi-
ciency would result in an enhance inflammasome activation via
a ROS-dependent mechanism. Surprisingly, our findings sug-
gest a positive effect of Nrf2 in the activation of the NLRP3 and
AIM2 inflammasome but not the NLRC4 inflammasome. Fur-
thermore, Nrf2 is the major target of ROS inhibition and is
essential for ROS-induced inflammasome activation. From this
we can conclude that Nrf2 may play a proinflammatory role in
inflammasome-related diseases, particularly in the context of
metabolic disorders. Interestingly, several studies reported that
Nrf2 deficiency attenuates the development of atherosclerosis,
obesity, and insulin resistance (27–31).
During our investigation of mechanism by which Nrf2 medi-
ates inflammasome activation, we found that Nrf2 is not
required for the transcription of genes encoding inflammasome
components including Nlrp3, Pycard, Casp1, and Il1b. This
finding suggested that several potential mechanisms may exist.
First, we observed the appearance of Nrf2 in cytosolic ASC-
enriched compartments after NLRP3 inflammasome activa-
tion, suggesting that cytosolic Nrf2 may contribute to the
assembly of ASC speck. This possibility is reinforced by the fact
that Nrf2 is accumulated in both cytosolic and nuclear com-
partments after LPS stimulation (49) and interacts with other
cytosolic cell stress responses such as autophagy (17). Further
in-depth biochemical analysis of the interaction between Nrf2
and other inflammasome-associated molecules may provide
mechanistic insight. Second, Nrf2 may mediate inflammasome
activation through transcriptional control of some unknown
factor(s). This mechanism can be further tested utilizing
microarray techniques. Third, a previous study reported that
gene deletion of superoxide dismutase 1 (Sod1) led to elevated
ROS generation, which inactivated caspase-1 through reversi-
ble oxidation of caspase-1 cysteine residues (50). However, it is
unlikely that Nrf2 directly targets on caspase-1, as we show that
Nrf2 is not required for NLRC4 inflammasome activation, indi-
cating Nrf2 may be targeting signaling molecules upstream of
caspase-1.
Accumulative evidence suggests that during inflammatory
response, various stress signaling pathways interact, and their
cross-regulations determine cell adaptive responses. Our find-
ings reveal a close relationship between oxidative stress and
inflammasome activation, both of which are controlled by Nrf2.
This is of special significance regarding cell stress response
against invading pathogens, including bacteria, virus, and fungi.
Recent studies suggest that Nrf2/ mice generally show an
exacerbated susceptibility against pathogen infection including
bacteria (24), viruses (23), and fungi (25). These observations
are unlikely to be explained by the anti-oxidative effect of Nrf2,
as it is largely accepted that enhanced ROS generation contrib-
utes to innate cell microbe elimination during respiratory burst.
Interestingly, it has been well documented that inflammasome
activation plays an essential role against invading various
pathogens (7). Our findings suggest that Nrf2 is a pivotal medi-
ator of inflammasome activation, thus highlighting the possi-
bility that Nrf2 controls pathogen infection by activating
inflammasomes. More recently, the importance of Nrf2 func-
tion has been effectively utilized clinically. Nrf2-targeted ther-
apeutic regimen has been Food and Drug Administration-ap-
proved in the treatment of patients with relapsing-remitting
multiple sclerosis. As this transcription factor has proven to be
a practical target, it will be of great clinical significance to inves-
FIGURE 6. Nrf2/ mice showed attenuated inflammation in alum-induced peritonitis. A–D, WT or Nrf2/ mice were intraperitoneally injected with alum
(400 g/per mouse) diluted in sterile PBS. n 	 6 mice per group. Sixteen hour after alum injection, peritoneal lavage was performed. Absolute number of
peritoneal exudate cells (PEC) (A), CD11bLy-6G neutrophils (B), and CD11bLy-6C inflammatory monocytes (C) was evaluated by FACS analysis. Cytospin
preparation followed by H&E staining was performed (D). E, WT or Nrf2/ mice were intraperitoneally injected with alum (600 g/per mouse) diluted in sterile
PBS. n 	 5 mice per group. Peritoneal lavage was performed 4 h after injection. IL-1 was measured by ELISA. Values are expressed as the mean  S.D., and the
results are representative of two independent experiments. *, p  0.05, versus controls.
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tigate the effect of Nrf2 in inflammasome activation during the
context of pathogen infections.
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